Contains Nonbinding Recommendations

Draft - Not for Implementation

Draft Guidance on Loperamide Hydrochloride; Simethicone
August 2022

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

This guidance, which interprets the Agency’s regulations on bioequivalence at 21 CFR part 320, provides product-specific recommendations on, among other things, the design of bioequivalence studies to support abbreviated new drug applications (ANDAs) for the referenced drug product. FDA is publishing this guidance to further facilitate generic drug product availability and to assist the generic pharmaceutical industry with identifying the most appropriate methodology for developing drugs and generating evidence needed to support ANDA approval for generic versions of this product.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA guidances means that something is suggested or recommended, but not required.

This is a new draft product-specific guidance for industry on generic loperamide hydrochloride; simethicone.

Active Ingredients: Loperamide hydrochloride; Simethicone

Dosage Form; Route: Tablet, chewable; oral

Recommended Studies: Two in vivo bioequivalence studies with pharmacokinetic endpoints and one in vitro defoaming study

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 2 mg; 125 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comment: The tablet should be chewed, then swallowed with water.
2. **Type of study:** Fed  
   **Design:** Single-dose, two-treatment, two-period crossover in vivo  
   **Strength:** 2 mg; 125 mg  
   **Subjects:** Males and non-pregnant, non-lactating females, general population  
   **Additional comment:** See comment above.

3. **Type of study:** In vitro  
   Conduct the U.S. Pharmacopeia (USP) in vitro defoaming study to measure the functional ability of simethicone to collapse bubbles produced by a foaming soap solution (1 g octoxynol-9/100 mL water). To demonstrate bioequivalence for the simethicone component, the following intro tests should be conducted: a) the USP in vitro defoaming testing, and b) the modified USP in vitro defoaming testing, wherein whole tablets are used instead of crushed tablets. The specification is a clear solution within 30 seconds.

**Analyte to measure:** Loperamide in plasma

**Bioequivalence based on (90% CI):** Loperamide

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Conduct comparative dissolution testing on 12 dosage units each of the test and reference products. Specifications will be determined upon review of the ANDA.

**Unique Agency Identifier:** PSG_020606